

Title (en)  
AROMATIC COMPOUND

Title (de)  
AROMATISCHE VERBINDUNG

Title (fr)  
COMPOSÉ AROMATIQUE

Publication  
**EP 3604267 A4 20201216 (EN)**

Application  
**EP 18775512 A 20180329**

Priority  
• JP 2017072811 A 20170331  
• JP 2018013514 W 20180329

Abstract (en)  
[origin: EP3604267A1] Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.

IPC 8 full level  
**C07C 59/72** (2006.01); **A61K 31/192** (2006.01); **A61K 31/4412** (2006.01); **A61K 31/444** (2006.01); **A61K 31/451** (2006.01); **A61K 31/4523** (2006.01); **A61K 31/454** (2006.01); **A61K 31/4545** (2006.01); **A61K 31/497** (2006.01); **A61K 31/506** (2006.01); **A61P 3/10** (2006.01); **C07D 211/22** (2006.01); **C07D 213/64** (2006.01); **C07D 401/04** (2006.01); **C07D 401/10** (2006.01); **C07D 401/12** (2006.01); **C07D 401/14** (2006.01); **C07D 413/10** (2006.01)

CPC (source: EP US)  
**A61K 31/192** (2013.01 - EP); **A61K 31/195** (2013.01 - EP); **A61K 31/44** (2013.01 - EP); **A61K 31/444** (2013.01 - EP); **A61K 31/451** (2013.01 - EP); **A61K 31/4523** (2013.01 - EP); **A61K 31/453** (2013.01 - EP); **A61K 31/454** (2013.01 - EP); **A61K 31/4545** (2013.01 - EP); **A61K 31/497** (2013.01 - EP); **A61K 31/501** (2013.01 - EP); **A61K 31/506** (2013.01 - EP); **A61P 3/10** (2017.12 - EP); **C07C 59/72** (2013.01 - EP US); **C07D 211/22** (2013.01 - EP US); **C07D 213/64** (2013.01 - EP US); **C07D 401/04** (2013.01 - EP); **C07D 401/10** (2013.01 - EP US); **C07D 401/12** (2013.01 - EP US); **C07D 401/14** (2013.01 - EP US); **C07D 413/10** (2013.01 - EP US); **C07C 2601/02** (2017.04 - EP); **C07C 2601/14** (2017.04 - EP)

Citation (search report)  
• [XY] EP 3031799 A1 20160615 - TAKEDA PHARMACEUTICAL [JP]  
• [E] WO 2018182050 A1 20181004 - TAKEDA PHARMACEUTICALS CO [JP], et al  
• [Y] US 2009137561 A1 20090528 - BROWN SEAN P [US], et al  
• [I] US 2016332968 A1 20161117 - CHOBANIAN HARRY [US], et al  
• See references of WO 2018181847A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**EP 3604267 A1 20200205**; **EP 3604267 A4 20201216**; CA 3058578 A1 20181004; CN 110719903 A 20200121; JP WO2018181847 A1 20200305; US 11186565 B2 20211130; US 2020039957 A1 20200206; WO 2018181847 A1 20181004

DOCDB simple family (application)  
**EP 18775512 A 20180329**; CA 3058578 A 20180329; CN 201880036029 A 20180329; JP 2018013514 W 20180329; JP 2019510211 A 20180329; US 201816499432 A 20180329